$8.2B US merger of Viterra and Bunge now complete
The deal was confirmed in a news release issued by the Missouri-based Bunge on Wednesday. It comes nearly six months after the Canadian government approved the merger with Viterra, formerly known as the Saskatchewan Wheat Pool.
The deal was heavily criticized by agricultural producers, who fear it will reduce competition in the grain and canola markets.
That fear was detailed in a report issued in April 2024 by the Competition Bureau, which found the deal was likely to hurt competition in those markets.
It also found that Bunge, the world's largest oilseed processing company, could influence the behaviour of G3 Global Holdings, a major competitor to Viterra.
Transport Canada says strict and legally binding controls are needed on U.S.-based Bunge's minority ownership stake in G3 to ensure it can't influence that company's pricing or investment decisions.
Among the restrictions placed on the merger by Ottawa are a commitment to maintain Viterra's head office in Regina for at least five years and an investment of at least $520 million in Canada within the next five years.
According to a media release, Bunge's CEO Greg Heckman stated that the merger creates a more robust organization with enhanced capabilities and expertise.
As part of the new structure, former Viterra CEO David Mattiske now serves as co-chief operating officer on Bunge's executive leadership team. He joins Julio Garros, who previously held the role of Bunge's co-president of agribusiness.
Viterra operates more than 80 grain-handling facilities across Canada.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Abcourt Mines finalises $8m loan to reopen Sleeping Giant mine in Quebec
Abcourt Mines has finalised a $8m secured financing facility with Nebari Natural Resources Credit Fund II in a critical step towards reopening the Sleeping Giant mine in Quebec, Canada. The Sleeping Giant is situated midway between Amos and Matagami in the Abitibi region of Quebec and falls within the jurisdiction of the Quebec government's Plan Nord. The property comprises four mining leases spanning 458 hectares, and 69 mining claims. The 36-month loan agreement bears interest based on a floating rate per annum, combining the three-month term secured overnight financing rate (SOFR) and an additional 12% per annum. The SOFR will be considered as 4% if it falls below this threshold. The facility allows for early repayment after the first year, with a 25% absolute return on the prepaid principal amount for the lender. Abcourt has issued 87,040,000 non-transferable warrants to the lender, exercisable at C$0.0625 per common share until 3 July 2028, with terms subject to adjustments based on prepayments and TSX Venture Exchange policies. Abcourt president and CEO Pascal Hamelin stated: 'Closing this transaction with Nebari is a major step toward starting production at the Sleeping Giant mine. 'This investment of $8m of non-dilutive capital offers us solid operational flexibility going forward and allows the company to develop the Sleeping Giant mine toward a commercial production status.' The company has also incurred an arrangement fee of $120,000 and will pay a monthly administration fee of $2,500 post-closing date. Security arrangements for the loan include a priority senior security on all of Abcourt's properties, subject to certain permitted liens. This encompasses real property interests, mining rights, inventory and equipment. The funds will be utilised for essential operations to initiate gold production. Immediate plans include constructing a sleep camp and kitchen, continuing work on tailing facilities, commencing production in the upper level of the mine and developing lower levels to open new mining fronts. "Abcourt Mines finalises $8m loan to reopen Sleeping Giant mine in Quebec" was originally created and published by Mining Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Posthaste: Canadian dollar could hit 78 cents U.S. and sooner than expected, says Scotiabank analyst
Currency analysts at Scotiabank say it's possible the Canadian dollar could rise to as high as 78 cents U.S. against the greenback by the end of this year instead of 2026 on a deteriorating outlook for the loonie's American counterpart 'We remain a bit more bullish on the CAD (Canadian dollar) outlook, bearish on the U.S. dollar than the Street consensus,' Shaun Osborne, chief FX strategist at Scotiabank Global FX Strategy, said during a webinar. The Canadian dollar has clocked a strong run over the last six months and is up 6.2 per cent against the U.S. dollar. Thursday alone, the loonie rose 0.5 per cent to an intraday high of 73.76 cents U.S. Conversely, the U.S. dollar index, which measures the greenback's performance against a basket of other major currencies including the Canadian dollar, has fallen nearly 11 per cent in its worst performance over six straight months since the 1970s, and its worst first-half showing since 2017. 'A six-month run (down) is pretty unusual,' Osborne said. 'It does seem quite likely that even though we've seen this significant depreciation … in the past few months. That trend is very likely to continue.' Osborne forecast to the policies and actions of United States President Donald Trump, including his massive tax-cut bill, which is projected to increase U.S. debt by US$3.3 trillion. The bill passed its final legislative test on Thursday and was due to be signed into law by Trump by his July 4 deadline. 'It seems quite likely that we will see persistent deficits in the U.S. Over time we have seen a pretty strong relationship between the situation on the deficit side and the evolution of the U.S. dollar,' he said. Osborne also said the 'potential erosion of Fed (U.S. Federal Reserve) independence is another worry for investors at a time where inflationary pressures still seem to be simmering,' which is another headwind for the U.S. dollar's performance. On Wednesday, Trump said in a Truth Social post that Federal Reserve chair Jerome Powell was 'too late' and 'should resign immediately.' The U.S. dollar could decline further if Trump decides to name a 'shadow' chair who is amenable to the president's calls for lower interest rates. 'Given the exceptional returns from the U.S. economy and assets over the last 10 to 15 years, we think we are in a position where global investors have become over-indexed to U.S. dollar assets and they are wondering if that situation is wise and whether it should continue,' Osborne said. There were signs in April that investors were thinking exactly that when the largest net outflow from U.S. Treasuries by Canadian investors ($57.8 billion) was recorded — also bad news for the greenback, but a definite boost to the loonie. On the plus side for the Canadian dollar, a TD Securities report from last week said if Canadian pension funds decide to repatriate U.S. investments to hedge against greenback losses, that flow of money back into Canada could provide a significant lift. TD Securities is currently calling for the Canadian dollar to rise 76 cents U.S. by December. Added Karl Schamotta, chief market strategist at Corpay Currency Research: 'As long as the slow-motion flight from the dollar continues, the loonie stands to benefit.' to get Posthaste delivered straight to your share of exports destined for the United States shrank to the smallest proportion since at least 1997, excluding the COVID pandemic. Shipments to other countries reached a new high, led by gold exports. Tariffs crushing exports and imports between Canada and its biggest trading partner, exports to other countries helped narrow the nation's trade deficit to $5.9 billion in May, from a record $7.6 billion in April, according to Statistics Canada data on Thursday. — Bloomberg Read the full story here. U.S. markets are closed for the July 4 holiday. Today's Data: S&P Global Canada services and composite purchasing managers indexes Companies caught in digital services tax crossfire as CRA won't issue refunds How does Canada's burgeoning LNG industry measure up to its ambitions? What's the fate of Canada's oil and gas as new era of nation-building dawns Markets just keep chugging along despite a bunch of apparent headwinds. Many investors worry about new highs, thinking the end is nigh but FP columnist Peter Hodson sees market records more as a confirmation of strength rather than a reason to sell. He explains why here. Financial Post published a feature on the death of the summer job as student unemployment reaches crisis levels. We want to hear directly from Canadians aged 15-24 about their summer job search. Send us your story, in 50-100 words, and we'll publish the best submissions in an upcoming edition of FP. You can submit your story by email to fp_economy@ under the subject heading 'Summer job stories.' Please include your name, your age, the city and province where you reside, and a phone number to reach you. Are you worried about having enough for retirement? Do you need to adjust your portfolio? Are you starting out or making a change and wondering how to build wealth? Are you trying to make ends meet? Drop us a line at wealth@ with your contact info and the gist of your problem and we'll find some experts to help you out while writing a Family Finance story about it (we'll keep your name out of it, of course). Want to learn more about mortgages? Mortgage strategist Robert McLister's Financial Post column can help navigate the complex sector, from the latest trends to financing opportunities you won't want to miss. Plus check his mortgage rate page for Canada's lowest national mortgage rates, updated daily. Visit the Financial Post's YouTube channel for interviews with Canada's leading experts in business, economics, housing, the energy sector and more. Today's Posthaste was written by Gigi Suhanic with additional reporting from Financial Post staff, The Canadian Press and Bloomberg. Have a story idea, pitch, embargoed report, or a suggestion for this newsletter? Email us at posthaste@ Posthaste: Canada home prices seen falling further as tariff war deepens downturn Posthaste: Canada is in for a rough couple of quarters, say economists Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Hemostemix Closes $469,366 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD $469,366. The Offering consisted of the issuance of 3,911,385 Common Shares at a price of CAD $0.12. As per TSXV Policy 4.1, the investor is arm's length to the Company and is not a Related Party to the Company at the time of disclosure. The use of proceeds will be allocated to general working capital purposes, supporting the Company's continuing operational expenses and business development activities. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed. All securities issued in connection with the Offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. ABOUT HEMOSTEMIXHemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in ten peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Closing of a non brokered private placement, in furtherance of sales in Florida of VesCell (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
